Loading
HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerisation. Activates MAPK signalling following TMPRSS13 cleavage and activation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant, naming MET Tyrosine Kinase Inhibitor SGX523. Open Targets scores its association with cancer at 0.78 (direct and indirect evidence; datatypes clinical 0.65, affected pathway 0.73, literature 1.00, genetic association 0.50, somatic mutation 0.83). IntOGen calls it a driver in 1 cohort (1 activating, 0 loss-of-function), covering Small Cell Lung Cancer. In OnCo, 1 product record names it (Ficlatuzumab).
In plain words · HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.
HGF (Hepatocyte growth factor) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Lung cancer, Gastric & gastro-oesophageal junction cancer, Skin cancer and 5 more.
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types.
No product in this corpus aims at HGF yet. Drugs fit a pocket that exists only in one shape of the mutant protein and hold it there, off.
Lineage antigen shared with normal granulocytes: HPA finds the gene lineage enriched in that blood lineage, and the 1 medicine aimed at it (Ficlatuzumab) act on the wild-type protein, so the normal lineage is hit too. HPA HGF: RNA tissue enriched (placenta 293 nTPM); blood lineage lineage enriched (granulocytes 95 nTPM); no normal tissue stained high; highest cancer staining breast cancer (2 of 11 high). Distribution: 5 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Lung cancer (all types), Gastric & gastro-oesophageal junction cancer, Skin cancer (all types), Ovarian cancer, Brain and spinal cord tumours (all types)); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 7 of scripts/fetch-target-specificity.ts.)
Sources: Human Protein Atlas HGF tissue; Human Protein Atlas HGF pathology; Open Targets ENSG00000019991 associations
First described 1989. Earliest sequence paper UniProt cites for the protein: Miyazawa et al, Biochem. Biophys. Res. Commun, 1989, "Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor". Source.
Sources: HGNC HGNC:4893 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt P14210 (protein name, function text, keywords and locations (REST API)); CIViC gene HGF (1 evidence items, 0 assertions, 1 variants; diseases: Glioblastoma (GraphQL API, CC0)); Open Targets ENSG00000019991 (association with cancer (MONDO_0004992) 0.78; per-cancer scores at or above 0.5: non-small cell lung carcinoma 0.54, gastric cancer 0.59, ovarian cancer 0.51, melanoma 0.55, skin cancer 0.55, lung cancer 0.62 (GraphQL API, CC0)); IntOGen HGF (driver in 1 cohort (Act 1, LoF 0); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Potent mitogen for mature parenchymal hepatocyte cells, seems to be a hepatotrophic factor, and acts as a growth factor for a broad spectrum of tissues and cell types. Activating ligand for the receptor tyrosine kinase MET by binding to it and promoting its dimerisation. Activates MAPK signalling following TMPRSS13 cleavage and activation. Locus 7q21.11 (HGNC).
RNA: tissue enriched (placenta 293 nTPM), detected in many normal tissues. Blood: lineage enriched (granulocytes 95 nTPM).
No normal tissue stained high; medium in Adrenal gland, Appendix, Breast, Bronchus, Caudate, Cerebellum and more.
Medium only: carcinoid, cervical cancer, glioma, head and neck cancer.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"HGF" OR ABSTRACT:"HGF" OR TITLE:"hepatocyte growth factor" OR ABSTRACT:"hepatocyte growth factor" OR TITLE:"Hepatocyte growth factor" OR ABSTRACT:"Hepatocyte growth factor" OR TITLE:"F-TCF" OR ABSTRACT:"F-TCF" OR TITLE:"DFNB39" OR ABSTRACT:"DFNB39") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about HGF, not a curated reading list.
Shares Receptor tyrosine kinase activation, Skin cancer (all types), CIViC, IntOGen.
Shares Invasion: proteases, adhesion & the invasive front, Glioma & glioblastoma, CIViC, IntOGen.
Shares Invasion: proteases, adhesion & the invasive front, CIViC, Open Targets Platform.
Shares Proteoglycans in cancer, CIViC, Gastric & gastro-oesophageal junction cancer, Ovarian cancer.
Shares Renal cell carcinoma (KEGG map), CIViC, Open Targets Platform.
Shares Receptor tyrosine kinase activation, Skin cancer (all types), CIViC, IntOGen.
Shares Receptor tyrosine kinase activation, CIViC, Open Targets Platform.
Shares Renal cell carcinoma (KEGG map), CIViC, IntOGen, Open Targets Platform.